Loading
A phase 2 trial of GC101 TIL, Dacarbazine, Temozolomide in melanoma, run by Shanghai Juncell Therapeutics, now recruiting.
A Study of GC101 TIL in Advanced Melanoma is a phase 2 interventional study registered as NCT06703398 by Shanghai Juncell Therapeutics, with 98 participants planned, started 2024-12-20 and due to reach its primary completion in 2026-05-12. Interventions recorded: GC101 TIL, dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai Juncell Therapeutics, GC101 TIL.
Shares Dacarbazine, Temozolomide, Advanced melanoma (unresectable stage III and stage IV), Paclitaxel / nab-paclitaxel.
Shares Dacarbazine, Temozolomide, Paclitaxel / nab-paclitaxel, Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Temozolomide, Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/